Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients.
about
Vitamin D compounds for people with chronic kidney disease not requiring dialysisIs there an association between elevated or low serum levels of phosphorus, parathyroid hormone, and calcium and mortality in patients with end stage renal disease? A meta-analysisAdministered paricalcitol dose and survival in hemodialysis patients: a marginal structural model analysisObservational studies versus randomized controlled trials: avenues to causal inference in nephrology.Associations of body mass index and weight loss with mortality in transplant-waitlisted maintenance hemodialysis patients.Association of hemodialysis treatment time and dose with mortality and the role of race and sex.Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals.Association of cumulatively low or high serum calcium levels with mortality in long-term hemodialysis patients.The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis.Vitamin D treatment and mortality in chronic kidney disease: a systematic review and meta-analysis.The relationship between ultraviolet light exposure and mortality in dialysis patientsRole of nutritional status and inflammation in higher survival of African American and Hispanic hemodialysis patientsVitamin D supplementation and mortality risk in chronic kidney disease: a meta-analysis of 20 observational studies.Vitamin D receptor agonist VS-105 improves cardiac function in the presence of enalapril in 5/6 nephrectomized rats.Impact of race on hyperparathyroidism, mineral disarrays, administered vitamin D mimetic, and survival in hemodialysis patients.VS-105: a novel vitamin D receptor modulator with cardiovascular protective effects.Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT studyParicalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT studyCardiorenal syndrome and vitamin D receptor activation in chronic kidney diseaseSurvival disparities within American and Israeli dialysis populations: learning from similarities and distinctions across race and ethnicity.Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study.Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patientsPotential for vitamin D receptor agonists in the treatment of cardiovascular disease.Selective vitamin D receptor activation as anti-inflammatory target in chronic kidney disease.The future of vitamin D analogs.Safety and tolerability of paricalcitol in patients with chronic kidney disease.The role of vitamin D receptor activation in chronic kidney diseaseTwo novel vitamin D receptor modulators with similar structures exhibit different hypercalcemic effects in 5/6 nephrectomized uremic rats.
P2860
Q24240439-13EA4066-0521-43DA-8932-8FCAD10EFAACQ27011288-1E158B0E-4686-4E68-9F37-A56507269215Q30408489-A61116D9-CFE9-456E-A551-AEC30B25FCBBQ30423049-735A445C-85C8-40E6-BDEC-7A5F9231A741Q30427552-60C6D74F-6C9D-43E9-8AB3-96C232FB52B8Q33578221-ED270393-F1F9-490B-9224-4D4FB7953C82Q33862710-4A02AF08-BDC4-4D58-A945-02F6922F589DQ34135288-6ED1DB22-C7DD-4215-89AC-1951A0D2252DQ34252401-D5F42E19-B425-4A8C-9809-1871B4D04074Q34610602-EF87F9CD-724A-4FA9-8863-6AF54279ADC1Q34812456-1B7ABBDB-87F3-4D49-9A63-3A68E92F07E4Q34850611-AE187EF9-084A-43CC-80B3-BD7AAB9FC4C9Q34997739-4DA29EC2-ABA8-407D-B1D3-AD3C4F510854Q35086461-7C3BE6E9-6525-49A7-9CC2-A1264CC758E1Q35229831-F3E3FE6F-0819-40DD-BE25-D9C0B5183E66Q35287391-9E03745F-D13C-4674-A28C-7DBE082388D5Q35920190-1A546D5A-F2D2-4F02-A893-ABC796068408Q36129859-C7FE8AD5-7768-40D1-B31E-85691D989C3BQ36468531-C35963FC-DE23-455B-8D90-12AFAA7A6C96Q36746271-6AC1D6AB-36E8-4F6E-82D6-84822F04D4E1Q37162738-347D9D73-5405-4001-9E3F-6A5681C876F5Q37214510-2F903F85-4BEF-4F5D-9411-A7686C5A8C4EQ37376932-C0D60B11-3108-4463-887B-A42EC39777DFQ37553481-4FBFEBF0-8FBE-41E9-B90A-DAFBA946FBB3Q37695300-F07AE27B-6020-4924-99FC-AA36989AE310Q38101995-1209D3F9-4630-4C90-A1FF-849B692F683BQ39747749-22703A45-AC25-4300-8A34-0B5159AF518DQ43658115-15D58987-94F7-48E2-989D-0D63B44C2BD4
P2860
Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Ratio of paricalcitol dosage t ...... tenance hemodialysis patients.
@en
type
label
Ratio of paricalcitol dosage t ...... tenance hemodialysis patients.
@en
prefLabel
Ratio of paricalcitol dosage t ...... tenance hemodialysis patients.
@en
P2093
P2860
P50
P356
P1476
Ratio of paricalcitol dosage t ...... tenance hemodialysis patients.
@en
P2093
Charles J McAllister
Christian S Shinaberger
David van Wyck
Sander Greenland
P2860
P304
P356
10.2215/CJN.01760408
P577
2008-08-13T00:00:00Z